Please login to the form below

Not currently logged in
Email:
Password:

Humira still the biggest pharma brand

The industry’s best-selling products revealed in the latest PMLiVE Top Pharma List figures
Humira - Abbott

AbbVie's flagship brand Humira continued its stellar performance last year to retain the top spot in the PMLiVE Top Pharma List ranking of the industry's 50 biggest products.

The ranking, produced exclusively for PMLiVE by GlobalData, showed Humira (adalimumab) powered its way to the top of the 2013 chart on the back of sales that grew 20 per cent to $11.5bn.

Described early on in its life as a 'pipeline in a product' by its manufacturer, due to its potential in multiple lucrative indications, Humira's recent performance was assisted by new uses in areas such as ulcerative colitis and psoriasis.

The rheumatoid arthritis drug managed once again to keep at bay two of its fellow anti-TNF inhibitors, Johnson & Johnson's Remicade (infliximab) and Pfizer/Amgen's Enbrel (etanercept).

It also means that once again all of the top three products were biologic treatments, a category that is expected to show continued growth.

Elsewhere in the Top Pharma List's latest product rankings there was confirmation of strong performance from Sanofi's Lantus (insulin glargine), sales of which grew 15 per cent to $7.3bn last year.

Double-digit sales growth was also seen from Pfizer's fibromyalgia drug Lyrica (pregabalin), which GlobalData said made sales of $4.8bn in 2013, in the process overtaking Lipitor to become Pfizer's best-selling product.

The once-mighty cholesterol brand has been in free fall since it began to go off-patent in 2011 and generic competition had already cut a swathe through Lipitor's 2012 sales, which were reduced by more than half to $4.8bn. The decline was slightly less pronounced in 2013, but sales were still down by about a third to $3.1bn.

Visit the full PMLiVE Top Pharma List. It includes rankings of the 25 biggest companies and the full top 50 products ranking

Article by
Dominic Tyer

9th April 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics